Minerva Neurosciences, Inc. (NERV)
NASDAQ: NERV · IEX Real-Time Price · USD
3.140
-0.080 (-2.48%)
Jul 19, 2024, 12:00 AM EDT - Market open
Minerva Neurosciences Employees
Minerva Neurosciences had 9 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
9
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,511,527
Market Cap
21.96M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Trinity Biotech | 380 |
ImmunoPrecise Antibodies | 102 |
Ekso Bionics Holdings | 72 |
Apollomics | 45 |
Sol-Gel Technologies | 36 |
Gain Therapeutics | 32 |
Nephros | 31 |
TRxADE HEALTH | 8 |
NERV News
- 2 months ago - Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates - GlobeNewsWire
- 5 months ago - US FDA declines to approve Minerva Neurosciences' schizophrenia drug - Reuters
- 5 months ago - Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates - GlobeNewsWire
- 9 months ago - Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates - GlobeNewsWire
- 1 year ago - Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates - GlobeNewsWire
- 1 year ago - Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market - GlobeNewsWire
- 1 year ago - Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates - GlobeNewsWire
- 1 year ago - Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia - GlobeNewsWire